On Monday, April 1, we announced our plans to acquire Chemistry Holdings, a formulation technology company that is developing innovative delivery systems for the nutraceutical and pharmaceutical industry.

An Expansion of Our Platform
With this acquisition, we expect to expand our platform of oral dosage forms beyond dissolving films. We will also seek to combine proprietary encapsulation techniques within this broader range of dosage forms. Why is this valuable? A growing number of drugs in the pipeline, including cannabinoid molecules are poorly soluble with low bioavailability. Innovative strategies are needed to overcome these limitations. The technology we are acquiring will allow us to pursue multiple encapsulation methods for improving the solubility of active ingredients. Furthermore, with novel dosage forms like the chewable pods, gram-range doses of active ingredients can be delivered, well above the limits of oral dissolving films.

With our broader tool box, we may pursue a wider range of products and address more consumer needs. Below, we answer common questions on the deal terms.

FAQs

Updated May 14, 2019

Q: Where can I reference the original announcement? 
A: Please refer to the press release issued on April 1, 2019.

Q: You are issuing 5,700,000 shares upfront. What are you getting?
A: For 5,700,000 shares, we will be acquiring the company